Compare HDFC Bank Limited Common Stock (HDB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HDFC Bank Limited Common Stock vs Organon & Co. Common Stock — how do they compare? HDFC Bank Limited Common Stock trades at $23 (market cap $114.94B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: HDFC Bank Limited Common Stock is far larger — about 31.8× Organon & Co. Common Stock's market cap, and HDFC Bank Limited Common Stock pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| HDB | OGN | |
|---|---|---|
Market Cap | $114.94B | $3.62B |
Volume | 6,516,078 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $37.18 | $13.81 |
52-Week Low | $21.84 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.23T | $11.04B |
Dividend Yield | 1.8% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HDFC Bank Limited Common Stock
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
